Literature DB >> 26617813

Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance.

Lili Wang1, Chenxu Wang2, Shanshan Jin3, Donghui Qu4, Huanchun Ying1.   

Abstract

The present study aims to investigate the relationship of NF-κB p65 and PTEN protein with chemotherapy resistance in ovarian cancer by measuring their expression in primary epithelial ovarian cancer, and to explore the correlation of the expression of these two proteins with ovarian carcinoma and their clinical significance. Ovarian cancer patients (n = 161) were divided into two groups: sensitive group (n = 82) and resistant group (n = 79). Expression of NF-κB p65 and PTEN protein in the ovarian cancer tissues was determined using immunohistochemistry to assess the relationship and correlation between the expression levels of these two proteins and chemotherapy resistance of ovarian carcinoma. The Cox model was used to analyze the independent risk factors associated with ovarian cancer prognosis. The expression of NF-κB p65 in the sensitive group (68.29%) was lower than that of the resistant group (94.94%). In contrast, the expression of PTEN protein in the sensitive group (50.00%) was higher than that of the resistant group (17.72%). Expression of NF-κB p65 was negatively correlated with that of PTEN protein in ovarian cancer tissue (rs = -0.246, P = 0.002). Expression of NF-κB p65 or PTEN protein and surgical stage of ovarian cancer were independent risk factors associated with chemoresistance (all P < 0.05). Low expression of PTEN and high expression of NF-κB are significant risk factors for chemotherapy resistance of ovarian cancer patients.

Entities:  

Keywords:  NF-κB; PTEN; chemoresistance; immunohistochemistry; ovarian epithelial cancer

Mesh:

Substances:

Year:  2015        PMID: 26617813      PMCID: PMC4637628     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  41 in total

1.  Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.

Authors:  C Montagut; I Tusquets; B Ferrer; J M Corominas; B Bellosillo; C Campas; M Suarez; X Fabregat; E Campo; P Gascon; S Serrano; P L Fernandez; A Rovira; J Albanell
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

Review 2.  PTEN, a general negative regulator of cyclin D expression.

Authors:  Lirong Diao; Ye-Guang Chen
Journal:  Cell Res       Date:  2007-04       Impact factor: 25.617

3.  Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue.

Authors:  N Sasaki; T Morisaki; K Hashizume; T Yao; M Tsuneyoshi; H Noshiro; K Nakamura; T Yamanaka; A Uchiyama; M Tanaka; M Katano
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 4.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

Review 5.  Structure, regulation and function of NF-kappa B.

Authors:  U Siebenlist; G Franzoso; K Brown
Journal:  Annu Rev Cell Biol       Date:  1994

6.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

7.  [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].

Authors:  Hui-Juan Wu; Hai-Tao Wu; Dan-Hui Weng; Hui Xing; Yun-Ping Lu; Ding Ma
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2007-09

8.  PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.

Authors:  Sanae Bouali; Anne-Sophie Chrétien; Carole Ramacci; Marie Rouyer; Philippe Becuwe; Jean-Louis Merlin
Journal:  Oncol Rep       Date:  2009-03       Impact factor: 3.906

9.  Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.

Authors:  Xiaojuan Yan; Michael Fraser; Qing Qiu; Benjamin K Tsang
Journal:  Gynecol Oncol       Date:  2006-03-20       Impact factor: 5.482

10.  MCP-1 promotes invasion and adhesion of human ovarian cancer cells.

Authors:  Shigenori Furukawa; Shu Soeda; Yuichiro Kiko; Osamu Suzuki; Yuko Hashimoto; Takafumi Watanabe; Hiroshi Nishiyama; Kazuhiro Tasaki; Hiroshi Hojo; Masafumi Abe; Keiya Fujimori
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480

View more
  9 in total

1.  LncRNA MEG3 impacts proliferation, invasion, and migration of ovarian cancer cells through regulating PTEN.

Authors:  Juelan Wang; Wenqian Xu; Yangke He; Qi Xia; Siwei Liu
Journal:  Inflamm Res       Date:  2018-10-11       Impact factor: 4.575

2.  High Expression of Nuclear Transcription Factor-κB is Associated with Cisplatin Resistance and Prognosis for Ovarian Cancer.

Authors:  Yanyan Kan; Juntian Liu; Fangxuan Li
Journal:  Cancer Manag Res       Date:  2020-09-09       Impact factor: 3.989

3.  Anti-oncogenic PTEN induces ovarian cancer cell senescence by targeting P21.

Authors:  Xiaoping Ke; Li Li; Jingwei Li; Mengyu Zheng; Ping Liu
Journal:  Cell Biol Int       Date:  2021-10-19       Impact factor: 4.473

Review 4.  NF-κB Signaling in Ovarian Cancer.

Authors:  Brittney S Harrington; Christina M Annunziata
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

5.  Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.

Authors:  Michal Kielbik; Izabela Szulc-Kielbik; Magdalena Klink
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

Review 6.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

7.  Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer.

Authors:  Le Chen; Ying Yao; Lijuan Sun; Jie Tang
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

8.  Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer.

Authors:  Marianna Buttarelli; Marta De Donato; Giuseppina Raspaglio; Gabriele Babini; Alessandra Ciucci; Enrica Martinelli; Pina Baccaro; Tina Pasciuto; Anna Fagotti; Giovanni Scambia; Daniela Gallo
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

9.  Overcoming cisplatin resistance by targeting the MTDH-PTEN interaction in ovarian cancer with sera derived from rats exposed to Guizhi Fuling wan extract.

Authors:  Li Han; Xueyun Cao; Zhong Chen; Xiaojuan Guo; Lei Yang; Yubing Zhou; Hua Bian
Journal:  BMC Complement Med Ther       Date:  2020-02-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.